Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific Corporation director Cathy R. Smith filed an initial ownership report on Form 3. The filing shows indirect ownership of 141 shares of common stock as of February 18, 2026, held "By Trust." This is a disclosure of existing holdings, not a reported trade.
Boston Scientific Corporation expanded its Board of Directors and significantly increased its share repurchase capacity. The board grew from ten to twelve members with the appointment of Catherine R. Smith, CFO of Starbucks, and Christophe P. Weber, president and CEO of Takeda Pharmaceutical, effective February 18, 2026.
Smith joins the Audit and Nominating and Governance Committees, while Weber joins the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee as of February 23, 2026. Each will receive prorated non-employee director compensation, including a cash retainer of approximately $24,663 and an equity award valued at approximately $42,420, vesting at the end of their terms.
The board also approved an increase to the company’s existing common stock repurchase authorization by an additional $4.0 billion, bringing the total authorization to $5.0 billion, all of which remains available under the stock repurchase program.
Boston Scientific EVP Padraig Andrew O'Connor reported multiple equity award transactions. On February 13, 14, and 16, 2026, restricted stock units covering 500, 1,190, and 905 units were exercised or converted into an equal number of Boston Scientific common shares at a stated price of $0.00 per share.
Related Form 4 entries show dispositions of 199, 449, and 339 common shares at $74.73 per share, characterized as payments of tax liability by delivering shares rather than open-market sales. Footnotes explain that each restricted stock unit represents a commitment to issue one share, generally in four equal annual installments beginning on specified February anniversaries of the grant dates.
Boston Scientific SVP Emily Woodworth reported several equity transactions involving restricted stock units and common stock. On February 13–16, 2026, she exercised restricted stock units that convert into an equal number of Boston Scientific common shares, with individual transactions including 1,413, 661, and 637 units. Corresponding common stock entries show the same share amounts acquired at a stated price of $0.0000 per share, reflecting non-cash derivative exercises. Additional common stock entries coded “F” cover 690, 296, and 283 shares delivered at $74.73 per share to satisfy tax liabilities rather than open-market sales. Footnotes state that each restricted stock unit represents a commitment to issue one share of common stock, generally in four equal annual installments beginning on specific grant anniversaries.
Boston Scientific EVP and CFO Jonathan Monson reported a series of equity award transactions. On February 13, 14 and 16, 2026, restricted stock units were converted into common stock in blocks of 1,766, 1,058 and 990 shares at $0.0000 per share, reflecting vesting of prior grants. On each date, portions of the resulting common shares (788, 470 and 440 shares) were disposed of at $74.73 per share to satisfy tax obligations through share withholding. Following these transactions, Monson directly owned 37,986 shares of Boston Scientific common stock.
Boston Scientific senior vice president and chief HR officer Miriam O'Sullivan reported multiple equity award transactions in mid‑February. She exercised restricted stock units into 588, 1,124, and 990 shares of common stock on February 13, 14, and 16, 2026 at a price of $0.00 per share.
To cover tax obligations, she disposed of 200, 329, and 291 common shares on the same dates through tax‑withholding transactions at $74.73 per share. After these moves, she directly held 17,302 Boston Scientific shares and indirectly held 1,731 shares through her spouse.
Boston Scientific Corp Chairman, President & CEO Michael F. Mahoney reported multiple equity award and vesting transactions. On February 13, 2026, he acquired 132,190 shares of common stock as a grant and another 8,832 shares through the conversion of restricted stock units, while 132,099 shares of common stock were withheld at $74.73 per share to cover tax obligations.
On February 14, 2026, 16,524 restricted stock units converted into 16,524 common shares, with 7,990 shares withheld for taxes at $74.73 per share. On February 16, 2026, 16,265 restricted stock units converted into common stock and 7,865 shares were similarly withheld for taxes at $74.73 per share.
The filing notes performance share units granted in February 2023 under organic net sales and total shareholder return programs, for which performance and service conditions were satisfied as of February 13, 2026. An additional 213,679 common shares are reported as held indirectly by trust.
Boston Scientific executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported multiple stock-based compensation transactions. He acquired Boston Scientific common stock through exercises of restricted stock units and performance share units, as well as grants totaling 34,898 shares of common stock on February 13, 2026.
On February 13, 14, and 16, 2026, he also had shares of common stock withheld to satisfy tax liabilities, disposing of 33,104, 1,990, and 1,806 shares at $74.73 per share, respectively, as tax-withholding dispositions rather than open-market sales. After these transactions, he directly held 213,907 shares of common stock, and 5,234 additional shares were reported as held indirectly by his child, for which he disclaims beneficial ownership.
Boston Scientific EVP Arthur C. Butcher reported multiple equity transactions in company stock and units. On February 13, 2026, he acquired 25,380 shares of common stock in two grant or award acquisitions, and also acquired shares through exercises of restricted stock units tied to long‑term incentive programs. He disposed of 25,150 shares of common stock on February 13, 2026 and smaller amounts on later dates to cover tax liabilities at $74.73 per share. Following these moves, he directly held 55,792 shares of common stock and indirectly held 13,354 shares through the company 401(k) plan.
Boston Scientific EVP, GC and Corporate Secretary Vance R. Brown reported multiple equity compensation transactions. On February 13–16, 2026, he acquired Boston Scientific common stock through the exercise and conversion of restricted stock units and performance share units, and through grants and awards, all at a stated price of $0.00 per share.
On these dates, shares of common stock were also disposed of at $74.73 per share to satisfy tax liabilities by delivering securities. Footnotes explain that performance share units granted on February 14, 2023 vested based on three-year total shareholder return and organic net sales performance through December 31, 2025, subject to a three-year service period satisfied on February 13, 2026. Each restricted stock unit represents a commitment to issue one share in four equal annual installments beginning on specified anniversaries of the grant dates.